Research abstract
Drug resistant bacteria such as MRSA, and airborne-transmitted microbes such as influenza and TB, present
significant health issues, with major healthcare and economic consequences. UV light is a well-established
highly-efficient anti-microbial modality, effective both against both bacteria and viruses. However it is not
possible to use UV sterilization in scenarios where people are present because it is both carcinogenic and
cataractogenic. Based on basic physics principles and supported by our Preliminary and Phase I Studies, far-
UVC light (~222 nm generated from a KrCl excimer lamp) has all the anti-microbial advantages of conventional
germicidal UV lamps, but without the corresponding human safety hazards. Thus the many demonstrated in-air
anti-microbial applications of germicidal UV lamps, which cannot currently be applied when humans are
present, can now be considered as potentially practical in the presence of humans.
The market is twofold: Initially for hospitals, in operating rooms for irradiating above incisions during surgery to
reduce surgical site infection rates. Secondly for public locations such as schools, hospitals, doctors offices,
airports, airplanes and the food preparation industry, to reduce airborne transmission of viruses including
influenza and measles, and bacteria such as TB. A key advantage is that UV bacterial killing is independent of
drug resistance, so our approach addresses the ever-growing issue of “superbugs”.
Neither higher (andgt;230 nm) nor lower (andlt;200 nm) wavelengths have the desired properties. Our products will be
inexpensive, long-lived far-UVC excimer lamps, emitting at 222 nm and with minimal higher-wavelength
emission. No such 222 nm lamp is currently available and, without a new technological breakthrough,
appropriate LEDs are not practical in the relevant wavelength range below 230 nm.
In Phase I we developed a high-intensity 222 nm excimer lamp with a lifetime of andgt;5,000 h, and minimal
emissions at higher wavelengths. In Phase II we will design, fabricate and test large area (andgt;300 cm2) 222 nm
excimer lamps with a further 5-fold intensity increase to andgt;20 mW/cm2. Fabrication processes will be optimized
to reduce costs and a matching filtered power supply developed.
222 nm light is safe for human exposure based on pure physics: 222 nm light cannot penetrate through the
skin outer dead cell layer, nor the eyeandapos;s surface tear film layer, nor into skin microbiome biofilms. This has been
confirmed with our short-term safety studies, but we recognize the need for confirmatory long-term safety data.
In Phase I we demonstrated that 222 nm light does not cause biological damage to the skin or eye, using
relevant short-term in-vivo endpoints. In Phase II we will extend these in-vivo safety studies to prolonged
(60 weeks) far-UVC exposures and long-term endpoints (skin cancer, skin microbiome, ocular damage).
A conventional germicidal UV lamp designed for management of bacteria in open wounds has FDA 510(k)
approval and will be the primary predicate device for our initial 510(k) applicationUV light is a well-established highly-efficient anti-microbial modality, effective both against both bacteria and
viruses - but it is not practical to use UV sterilization in scenarios where people are present because it is a
human health hazard, being both carcinogenic and cataractogenic. Based on physical principles and
supported by our earlier and Phase I Studies, far-UVC light (~222 nm) from a KrCl excimer lamp has all the
anti-microbial advantages of conventional germicidal UV lamps, but without the corresponding human safety
hazards. Our products will be inexpensive, long-lifetime far-UVC excimer lamps, emitting at 222 nm and with
minimal higher-wavelength emission, and we expect it to have a unique market both for surgical settings to
safely reduce Surgical Site Infections, and also for public locations such as doctors offices, airplanes, schools
and food preparation areas, to safely prevent airborne transmission of common viruses and bacteria such as
influenza and TB.
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
Verified by an exact topic code match. This is not a text-similarity match.
15 SBIR/STTR records share this UEI (2009–2025). Reported award amounts total $8,376,441. Reported amounts are not federal obligations.
Agencies: Department of Energy, Department of Health and Human Services, Department of Defense, Department of Agriculture